<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raden Anita Indriyanti</style></author><author><style face="normal" font="default" size="100%">Eko Fuji Ariyanto</style></author><author><style face="normal" font="default" size="100%">Hermin Aminah Usman</style></author><author><style face="normal" font="default" size="100%">Ristaniah Rose Effendy</style></author><author><style face="normal" font="default" size="100%">Diah Dhianawaty</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of Sinensetin and Imperatorin on A-549 lung cancer cell viability in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">A549</style></keyword><keyword><style  face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell viability</style></keyword><keyword><style  face="normal" font="default" size="100%">Imperatorin</style></keyword><keyword><style  face="normal" font="default" size="100%">Sinensetin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">38-46</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Lung cancer remains the leading cause of cancer death worldwide, so research is ongoing to discover new therapeutics, such as plant-derived bioactive compounds. For example, Sinensetin, a plant-derived polymethoxylated flavonoid, and Imperatorin, a natural furanocoumarin, have anti-cancer properties. This study assessed the effects of sinensetin and imperatorin separately and in combination on A-549 lung cancer cell viability. &lt;strong&gt;Method: &lt;/strong&gt;The A-549 lung cancer cell line was treated with sinensetin (60 μM), imperatorin (30 M), or a combination of both compounds (Sin:Imp 30:30 μM; 50:50 μM and 60:30 μM) for 48 hours. Cell viability was then assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and apoptosis was determined using fluorescein isothiocyanate (FITC) Annexin-V/Propidium iodide staining. &lt;strong&gt;Results: &lt;/strong&gt;The combination treatment of Sin:Imp 50:50 and Sin:Imp 60:30 μM reduced cell viability more than the individual treatment of sinensetin and imperatorin, with the lowest cell viability observed for the combination treatment of Sin:Imp 50:50 μM. Likewise, the combination treatment of Sin:Imp 50:50 μM induced the most apoptosis compared to individual treatment. &lt;strong&gt;Conclusion:&lt;/strong&gt; Sinensetin and imperatorin can decrease A-549 lung cancer cell viability and are potent apoptotic inducers, especially when they are used in combination, therefore they are potential lung cancer therapeutics.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">38</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Raden Anita Indriyanti&lt;sup&gt;1,2,*&lt;/sup&gt;, Eko Fuji Ariyanto&lt;sup&gt;3&lt;/sup&gt;, Hermin Aminah Usman&lt;sup&gt;4&lt;/sup&gt;, Ristaniah Rose Effendy&lt;sup&gt;5&lt;/sup&gt;, Diah Dhianawaty&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pharmacology, Faculty of Medicine, Bandung Islamic University, Bandung, West Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Doctoral Program in Medical Science, Faculty of Medicine, Padjadjaran University, Bandung, West Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Biomedical Sciences, Division of Biochemistry and Molecular Biology, Faculty of Medicine, Padjadjaran University, Bandung, West Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department Pathology Anatomy, Faculty of Medicine, Padjadjaran University, Bandung, West Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Radiology, Faculty of Medicine, Padjadjaran University, Bandung, West Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>